Investors and partners increasingly seek clear clinical differentiation, credible execution, and a realistic path from science to patients and commercial viability.
2
Experts warn that underinvestment in early translational research could weaken the pipeline of companies and programs.
3
Manufacturing strategy, scalability, and cost control should be addressed early because they affect commercialization and patient access.
4
Companies are pursuing partnerships, licensing, mergers and acquisitions, and other financing approaches to support survival and further validation.
5
Experts emphasize focused programs that address unmet clinical needs, demonstrate efficacy, and offer practical delivery and real-world value.
